#21 – Cancer Vaccines: How the Immune System Learns to Recognize Tumors
This time it's not about a virus, but about one of the most exciting developments in modern medicine: therapeutic cancer vaccines based on mRNA. Florian Krammer explains the basic principle — how a patient's tumor is sequenced, how the mutated genes (so-called neoantigens) are turned into a personalized vaccine, and how that vaccine trains the immune system to recognize and destroy cancer cells. Two recent trials show just how promising the approach is: a BioNTech vaccine against the notoriously aggressive pancreatic cancer, and a Moderna/Merck vaccine against melanoma, which now has five-year data. The vaccines aren't on the market yet and remain expensive to produce, but the direction is clear. Links to the original and follow up publications for the pancreatic cancer vaccine: https://www.nature.com/articles/s41586-023-06063-y https://www.nature.com/articles/s41586-024-08508-4 Links to the original and follow up publications for the melanoma vaccine (unfortunately partially behind paywalls): https://pubmed.ncbi.nlm.nih.gov/38246194/ https://pubmed.ncbi.nlm.nih.gov/42223134/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
- Transcript